Cancer Forums and News by PhD's


News | Forums

Go Back   Cancer Forums and News by PhD's > Cancer Forums and News

Cancer News

Breast
Colon
Kidney
Leukemia
Liver
Lung
Melanoma
Mesothelioma
Myeloma
Neck
Pancreatic
Prostate


Cancer Review

Breast
Colon
Kidney
Leukemia
Liver
Lung
Melanoma
Mesothelioma
Myeloma
Pancreatic
Prostate


Recent Forum Topics

 
decitabine
Modern Pathology - DNA methylation in breast and colorectal cancers
By Dross at 2007-07-14 00:09
 

Many drugs such as decitabine work to alleviate DNA Methylation (the addition of a ch3 group to a deoxycitidine nucleotide) which impedes access of dna transcription factors to the gene. Follwing is a link to a free article with an in depth look into the pathology of the process. 

 

Aberrant DNA methylation is one of the many potential causes for the abnormal growth of cancer cells, but it is also known to protect against intestinal cancer.4 Different types of cancers are associated with methylation of tumor suppressor genes and proto-oncogenes, causing alterations in functional gene expression. Cancer-specific DNA methylation patterns have been detected in free-floating DNA released from dead cancer cells.5, 48 A decrease in the expression of tumor suppressor genes correlates with an increase in methylation of DNA in the promoter region.49, 50 Aberrant methylation of tumor suppressor genes in many cancers, resulting in the downregulation of transcriptional activation, has been reported.

read more | 1356 reads

Pharmion Announces FDA Acceptance of IND for Oral Azacitidine
By Dross at 2007-01-31 20:19
 

Azacitidine, while causing a low cell count situation in which you will be more susceptible to infection, is very effective at putting patients into partial remissions. Depending on the chromosomal abnormalities you have, you should either be thankful you are in a partial remission or proceed directly to a stem cell therapy. Leave a comment in the forum for more information.

 

Pharmion Corporation (NASDAQ:PHRM) today announced that the Investigational New Drug (IND) application for the Company's oral formulation of azacitidine is now active following its acceptance by the U.S. Food and Drug Administration (FDA). The Company submitted the IND for oral azacitidine in December 2006.

read more | 2762 reads

UCLA Researchers Discover Genes Linked to Lymphoma, Opening Way for New Targeted Drugs
By Dross at 2007-01-31 00:43
 

 

Lymphomaterm is a blood cancer that affects more than 60,000 Americans each year.

 

Researchers at The University of California Los Angeles have identified genes that when inactivated help cause B-cell non-Hodgkin's lymphoma (NHL).

 

These genetic defects may also be involved in promoting the formation of other cancers since they can inactivate normal tumor-suppressing gene activities in a range of cell types. The team led by Michael Teitell, M.D., Ph.D., and funded by The Leukemiaterm & Lymphoma Society, used genetically engineered mice to accurately mimic human B-cell cancers. They had previously published research in which they identified frequent genetic abnormalities in cancer cells from NHL patients -- namely defects in the TCL1 gene -- and showed that TCL1 abnormalities can cause NHL in mice when accompanied by additional genetic defects. Now, they have found some of these cancer collaborators. Teitell's team used a powerful genetic technique called "restriction landmark genomic scanning" (RLGS) to find genes that work with abnormal TCL1 to promote lymphoma formation.

read more | 3841 reads

Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hemat
By admin at 2006-12-28 09:46
 

New Results from Kantarjian. Dosing levels for use of decitabine are still an ongoing question. Here Kantrajian et al. present new results from a phase one study of lowered but prolonged doses versus the standard 15mg/m2 for five days. Their results show a greater efficacy at the current 15mg/m2 dose.

[via Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies -- Issa et al. 103 (5): 1635 -- Blood]:

read more | 2657 reads

Syndicate content
 
Search

sponsored links




Donate


Newsletter



Subscribe to our newsletter to receive info on our site or upcoming clinical trials
Email

Confirm your email address

HTML format
State

Please select the newsletters you want to sign up to:

  • Cancerfocus
    Receive updates from Cancerfocus.
  • Breast
  • Colon
  • Kidney
  • Leukemia
  • Liver
  • Lung
  • Melanoma
  • Mesothelioma
  • Myeloma
  • Neck
  • Pancreatic
  • Prostate




Syndicate
Syndicate content


All times are GMT -5. The time now is 02:22 AM.